Modality
ASO
MOA
Anti-Tau
Target
USP1
Pathway
JAK/STAT
CLLMDS
Development Pipeline
Preclinical
~May 2016
→ ~Aug 2017
Phase 1
Nov 2017
Phase 1Current
NCT06721105
258 pts·CLL
2017-11→TBD·Recruiting
258 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Trial Timeline
P1/2
Recruit…
Recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06721105 | Phase 1/2 | CLL | Recruiting | 258 | ORR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| RHH-7558 | Roche | Phase 1 | SGLT2 | |
| NVS-5439 | Novartis | Preclinical | BET | |
| ABB-2476 | AbbVie | Phase 1/2 | USP1 | |
| NVO-9630 | Novo Nordisk | Phase 2 | CD3 | |
| REG-2172 | Regeneron | Phase 1/2 | PCSK9 | |
| BGN-3305 | BeiGene | Phase 2 | BCMA | |
| Sovarasimod | Halozyme | Phase 1/2 | WEE1 | |
| Voxamavacamten | Corcept | Approved | BET | |
| Zenonaritide | Arvinas | Phase 1/2 | BCL-2 | |
| Tezesotorasib | Enliven | Phase 2 | USP1 |